Patent · US Active

3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases

US11020379B2 · kind B2 · utility

1Cited by

7References

20Claims

0Family size

Assignees

EMORY UNIVERSITY · US
Children's Healthcare of Atlanta · US

Inventors

Nael McCarty · Atlanta, US
Guiying Cui · Shelby Charter Township, US

Key dates

Filing date	Nov 27, 2019
Grant date	Jun 1, 2021
Priority date	—
Expiry date	Nov 27, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N′-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.